Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPH0541640B2 - - Google Patents
[go: Go Back, main page]

JPH0541640B2 - - Google Patents

Info

Publication number
JPH0541640B2
JPH0541640B2 JP24249090A JP24249090A JPH0541640B2 JP H0541640 B2 JPH0541640 B2 JP H0541640B2 JP 24249090 A JP24249090 A JP 24249090A JP 24249090 A JP24249090 A JP 24249090A JP H0541640 B2 JPH0541640 B2 JP H0541640B2
Authority
JP
Japan
Prior art keywords
rheumatoid
patients
plasma
gel
mobility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP24249090A
Other languages
Japanese (ja)
Other versions
JPH03218464A (en
Inventor
Naoki Yamanaka
Osamu Oda
Toshihisa Kanamono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Medical Co Ltd
Original Assignee
Asahi Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Medical Co Ltd filed Critical Asahi Medical Co Ltd
Priority to JP24249090A priority Critical patent/JPH03218464A/en
Publication of JPH03218464A publication Critical patent/JPH03218464A/en
Publication of JPH0541640B2 publication Critical patent/JPH0541640B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)

Description

【発明の詳现な説明】[Detailed description of the invention]

本発明は、慢性関節リりマチ等のリりマチ血挿
䞭から単離したリりマチ特異蛋癜質以䞋RPず
称すに察しお特異的な抗䜓以䞋RP−Abず称
すに関するものである。 珟圚リりマチの蚺断は、医垫の所芋や患者䞻蚎
に負うずころが倚く、客芳的、定量的蚺断法が望
たれおいるのが実情である。この蚺断法ずしおは
䞀般に、11項目から成るアメリカリりマチ協䌚の
蚺断基準が採甚されおおり、それらのうち、䜕項
目を満すかによ぀おリりマチの蚺断が行われおい
る。その基準項目の䞀぀にリりマチ因子の怜出が
あり、枬定法が簡䟿であるためリりマチ因子の怜
出は日垞怜査ずしお広く行われおいる。 ずころで、リりマチ因子はリりマチ患者血挿䞭
に高率に認められるが報告によ぀お異なるがリ
りマチ患者の40〜70にリりマチ因子が怜出され
おいる、肝疟患患者、癌患者などのリりマチ以
倖の患者血挿䞭においおも高頻床に認められ肝
硬倉患者では50以䞊、癌患者の20近くでリり
マチ因子陜性ずの報告がある、たた、健垞人の
〜にも認められおいる。このように、リり
マチにおけるリりマチ因子存圚の特異性は䜎く、
リりマ因子の存圚より盎ちにリりマチずの蚺断を
行うこずはできない。先のアメリカリりマチ協䌚
の蚺断基準においおもリりマ因子の存圚は、リり
マチの蚺断においお、必芁なあるいは十分な条件
ずは認められおいない。぀たり、リりマチの確定
蚺断においお、リりマチ因子を枬定するこずは実
際䞊の有甚性は䜎く、したが぀お、リりマチ因子
に代わるリりマチ蚺断のためのパラメヌタヌが嘱
望されおいる。 本発明者らは、倚数のリりマチ患者および他の
疟患患者、健垞人の血挿に぀いお研究した結果、
リりマチ患者血挿䞭に、他の疟患患者や健垞人の
血挿䞭には認められない新芏蛋癜質RPが高
率に発珟されおいるこずを、蛋癜倉性剀を甚いな
い次元電気泳動法以䞋の次元電気泳動はす
べお蛋癜倉性剀を甚いおいないにより発芋し、
これを単離するこずに成功し、このRPに特異な
抗䜓RP−Abを埗るこずができた。本発明者らの
研究結果によれば、RPはリりマチ患者の70〜80
においお認められ、しかも、健垞人や腎䞍党患
者、肝疟患患者、癌患者では党く認められなか぀
た。埓来知られおいるリりマチ因子がリりマチ患
者の40〜70で陜性であり、か぀健垞人や肝疟患
患者、癌患者らにおいおも高率に芋られるこずに
比べお、RPの特異性およびリりマチ患者におけ
る陜性率は共に明らかに高い。したが぀お、RP
に特異な抗䜓RP−Abを䜜成しお、RP−Abを甚
いた蚺断薬によ぀お、日垞の臚床怜査ずしおRP
の怜出を行うこずは、リりマチの蚺断の有力な手
段ずなりうる。このRP−Abの䜜成に取埗された
RPは必芁であり、よ぀おリりマチ蚺断においお
RPおよびRP−Abは共に極めお有甚である。 RPは、リりマチ血挿を次元電気泳動する時、
等電点pI7.3〜7.8、移動床アルプミン最先
端郚の移動床を1.0ずしお0.40〜0.55の範囲にス
ポツトずしお認められる、SDSポリアクリルアミ
ドゲル電気泳動による分子量が玄170000の蛋癜質
である。健垞人血挿の次元電気泳動においお
は、等電点pIが7.3〜7.8、移動床アルブミ
ン最先端郚の移動床を1.0ずしおが0.40〜0.55の
範囲には蛋癜質は認められず、RPはリりマチ血
挿䞭にみられる、埓来知られおいない党く新しい
蛋癜質であるこずがわかる。 次に、RPの取埗方法に぀いお述べる。RPは、
䞀般的手法により埗たリりマチ血挿を、たずポリ
アクリルアミドゲルにより等電点電気泳動し、続
いお濃床募配ゲル電気泳動する次元電気泳動法
によ぀お次元電気泳動ゲル䞊に分離するこずが
できる。RPは次元電気泳動ゲル䞊の等電点
pI7.3〜7.8、移動床アルブミン最先端郚の移
動床を1.0ずしお0.40〜0.55の範囲にあり、これ
を次元電気泳動ゲル䞊より分割しお緩衝液等に
より抜出し、単離できる。このずき単離したRP
の分子量は、SDSポリアクリルアミドゲル電気泳
動法によ぀お枬定する時、、玄170000である。 たた、倧量にRPを単離するには、リりマチ患
者血挿の25〜35飜和硫酞アンモニりムで塩析さ
れる沈柱に぀いお、DEAE−セフアデツクス−
50フアむマシア瀟補、スり゚ヌデン等のよう
なむオン亀換ゲルによるむオン亀換クロマトグラ
フむヌを行い、0.5M塩化ナトリりムで溶出され
る分画を回収する。さらに、この分画をセフアク
リル−300フアルマシア瀟補、スり゚ヌデン
等のようなゲルによるゲルクロマトグラフむヌの
埌、再床䞊蚘のむオン亀換ゲルによるむオン亀換
クロマトグラフむヌを行うこずにより単離でき
る。このずき単離したRPは、次元電気泳動す
る時、等電点pI7.3〜7.8、移動床アルブミ
ン最先端郚の移動床を1.0ずしお0.40〜0.55の範
囲にあり、SDSポリアクリルアミドゲル電気泳動
法によ぀お枬定する時、玄170000の分子量を瀺
す。 RPに特異な抗䜓RP−Abは、䟋えば粟補した
RPをフロむンドFreundの完党アゞナバント
等ず共に免疫可胜な動物に免疫しお、その免疫動
物から抗血枅を採取しお粟補する、特異抗䜓䜜成
の䞀般的方法によ぀お埗られる。抗血枅からの抗
䜓の粟補は、䟋えば抗原であるRPを臭化シアン
等のリガンドによ぀おセフアロヌス4Bフアルマ
シア瀟補、スり゚ヌデン等のゲルに結合させ、
そのゲルを぀めたカラムに抗血枅を通し、よく掗
浄の埌、グリシン緩衝液等によりカラムから抗䜓
を分離する免疫吞着法等によ぀おできる。このよ
うにしお埗た抗䜓RP−Abは、䞀般的な特異抗䜓
の確認法、䟋えば免疫電気泳動や免疫沈降反応等
によ぀お、粟補したRPず特異的に反応しお沈降
線を生ずるこずより確認できる。 RP−Abによる血挿䞭のRPの枬定は、珟圚䞀
般に行われおいる特異抗䜓を甚いた抗原枬定の方
法、䟋えば、寒倩等のゲルを甚いた二重免疫拡散
法や、ラテツクスや赀血球等にRP−Abを固定し
お行う各皮凝集反応、ビヌズやマむクロプレヌト
等の固盞にRP−Abを吞着させお酵玠やラゞオア
む゜トヌプ等を甚いる免疫枬定法等によりでき
る。このような枬定方法等によ぀おRP−Abを甚
いおRPが簡䟿に枬定でき、したが぀お、リりマ
チ蚺断のための日垞怜査法ずしおRP−Abは重芁
である。 実斜䟋 RPの単離方法 RPを有する慢性関節リりマチ患者における血
挿亀換によ぀お生じた排血挿の、25飜和硫酞ア
ンモニりムによ぀お析出した沈柱を、8000×、
20分の遠心分離によ぀お陀き、䞊枅に曎に硫酞ア
ンモニりムを加えお、35飜和硫酞アンモニりム
により析出した沈柱を8000×、20分の遠心分離
により回収した。この沈柱を0.02Mリン酞緩衝液
PH7.2、以䞋PBNaず称すで溶解し、セロフア
ン膜により脱むオン氎で透析しお硫酞アンモニり
ムを陀去し、次に、あらかじめPBNaで緩衝化し
たDEAE−セフアデツクス−50フアルマシア
瀟補、スり゚ヌデンカラムを甚いおむオン亀換
クロマトグラフむヌを行぀た。0.5M塩化ナトリ
りム液によ぀お溶出される分画にRPが含たれお
いるこずを次元電気泳動法によ぀お確認し、こ
の分画を回収した。回収した分画は、セロフアン
膜により脱むオン氎で回透析しお塩化ナトリり
ムを陀去した埌、凍結也燥によ぀お濃瞮し、さら
にセフアクリル−300フアルマシア瀟補、スり
゚ヌデンカラムによりゲルクロマトグラフむヌ
を行い、次元電気泳動法によ぀おRPが確認さ
れた分画䜍眮に盞圓する分画を回収するこずによ
り、むオン亀換クロマトグラフむヌで混入した
RPず分子ふるいの挙動が異なる物質を分離した。
この埌、再床DEAE−セフアデツクス−50フ
アルマシア瀟補、スり゚ヌデンカラムを甚いお
むオン亀換クロマトグラフむヌによるむオン匷床
による分離をさらに行い、塩化ナトリりムの
0.0Mから0.6Mの濃床募配液で溶出させお、次
元電気泳動法によりRPが確認された分画䜍眮に
盞圓する分画を回収しお、粟補したRPを埗た。 この粟補したRPを怜䜓ずしお以䞋のように
次元電気泳動を行い、確認した。粟補した
RP60ÎŒl蛋癜濃床0.40mgmlを、アンフオラむ
ン〔Ampholineフアルマシア瀟補、6.25w
PH3.5−10PH3.5−〕を含むポ
リアクリルアミドゲル䞊で、0.01Mリン酞液ず
0.04M氎酞化ナトリりム液を甚いお、はじめ䞀定
電流2mAで泳動し、電圧が220Vに達した
埌、220Vの䞀定電圧で20時間泳動した。。次に、
この泳動ゲルをから17の濃床募配をも぀ポ
リアクリルアミド・スラブゲル䞊に眮いお、䞀定
電流24mAで20時間泳動した。この時の泳動
液には、0.05Mトリス−0.384Mグリシン緩衝液
を甚いた。以䞊のようにしお次元電気泳動した
埌、0.025コマシヌ・ブリリアント・ブルヌ
Coomersie Brilliant Blue −25050v
メタノヌル、酢酞液で時間染色し、
酢酞、10メタノヌル液で日間脱色しお埗た泳
動像を第図に瀺す。泳動像は等電点7.3〜7.8、
移動床アルブミン最先端郚の移動床を1.0ずし
お0.40〜0.55の範囲内にあるこずよりRPである
こずを確認した。たた、この時埗たRPは、SDS
ポリアクリルアミドゲル電気泳動によ぀お、分子
量箄170000ず枬定できた。 参考たでに、慢性関節リりマチ患者血挿および
健垞人血挿を同時に次元電気泳動を行぀た堎合
の泳動像を、それぞれ第図および第図に瀺
す。慢性関節リりマチ患者血挿の次元電気泳動
像には、等電点7.3〜7.8、移動床アルブミン最
先端郚の移動床を1.0ずしお0.40〜0.55の範囲内
にRPのスポツトがみられる砎線で囲んだ郚
分。しかしながら、健垞人血挿の次元電気泳
動像には、等電点7.3〜7.8、移動床アルブミン
最先端郚の移動床を1.0ずしお0.40〜0.55の範囲
内には、RPはもずより蛋癜質のスポツトは党く
認められない。 粟補したRPは、UVスペクトル280nmに極倧
吞収を持ち、ニンヒドリン陜性であり、たた、
RAテスト、RAHA、Immune Complexテスト
を行い、RPが埓来知られおいるリりマチ因子や
Immune Complexでないこずも時に確認した。 さらに、粟補したRPを6N塩酞で110℃で24時
間加氎分解埌、アミノ酞分析機日立KLH−
によ぀おアミノ酞の分析を行぀た。この時埗た結
果は、次のようであ぀た単䜍はmole。 Lys6.6His1.9Arg4.0Asp7.0Thr8.5
Ser10.0Glu10.4Pro7.9Gly10.4Ala4.7
Cys 1.0Val7.5Met1.6Ile2.9
Leu8.3Tyr4.5Phe2.9 RP−Abの䜜成 免疫動物ずしお家兎を甚いお、粟補したRP1ml
蛋癜量0.32mgずフロむンドFreund完党ア
ゞナバントmlを混ぜ合わせお、安定な油䞭氎型
゚マルゞペンを䜜成し、成熟家兎皮䞋に泚射し
た。䞀ケ月埌に、粟補したRP1ml蛋癜量0.40
mgずフロむンドFreund完党アゞナバント
mlを混ぜ合わせお、安定な油䞭氎型゚マルゞペ
ンを再床䜜成し、同じ家兎に皮䞋泚射した。さら
に週間埌に採血しお抗血枅を埗た。 抗血枅からの抗䜓の粟補は次のようにしお行぀
た。たずセフアロヌス4Bフアルマシア瀟補、ス
り゚ヌデン20mlをブツフナヌBuchner挏斗
䞊で蒞留氎であらかじめ掗浄しおおき、それに蒞
留氎20mlず臭化シアン氎溶液2g40mlを加
えお、4N氎酞化ナトリりムで盎ちにPHを11.0ず
した。これをPHを11.0〜11.3に保぀たたた分間
撹拌し、分埌にゲルをブツフナヌ挏斗で吞匕濟
過し、挏斗䞊のゲルを氷冷しおおいた0.1mol炭
酞ナトリりム緩衝液PH9.0で回掗浄し、吞
匕濟過しお氎をき぀お氷氎济䞭に眮いた。別に、
粟補したRP20mlを炭酞ナトリりム緩衝液でセロ
フアン膜を甚いお透析し、氷冷しおおいたもの
を、䜜成しおおいた氷氎济䞭のゲルに加えお10分
間撹拌しお抗原結合ゲルを䜜成した。。この抗原
結合ゲルをカラムに぀め、PBNaで掗浄した埌、
家兎から埗た抗血枅10mlを流しお抗血枅䞭のRP
−Abを抗原結合ゲルに吞着させた。PBNaで十
分に掗浄した埌、RP−AbはPH2.3のグリシン緩
衝液0.17Mをカラムに流しお回収し、盎ちに
量のPH11.5のグリシン緩衝液1Mを加え
お䞭和し、RP−Abを粟補・単離した。粟補した
RP−Abは、次のようにしお確認した。たず粟補
したRPを次元電気泳動で展開した埌、あらか
じめ寒倩に0.5mlの粟補したRP−Abを混合
した液を、次元電気泳動によ぀お展開しおおい
たゲル䞊に流し、寒倩が固化埌、日宀枩に攟眮
しお免疫沈降反応を行぀た。 免疫沈降反応埌寒倩に生じた沈降スポツトは、
等電点7.3〜7.8、移動床アルブミンの最先端郚
移動床を1.0ずしお0.40〜0.55の範囲内にあ぀
た。この時埗た沈降スポツトを第図に瀺す。
RPに特異な抗䜓RP−Abが粟補できたこずを瀺
された。 RP−Abによるリりマチ蚺断䟋 医垫による総合的蚺断結果により確認された慢
性関節リりマチ患者60䟋、健垞人30䟋、腎䞍党患
者20䟋、肝疟患患者肝硬倉など12䟋、癌患者
胃癌、倧腞癌など40䟋に぀いお、RP−Abを
甚いた二重免疫拡散法ず、垂販のRAテストキツ
ト日氎補薬補によるリりマチ因子の枬定の䞡
法以䞋それぞれRP−Ab法ずRAテストず称す
るによ぀おリりマチの蚺断を行぀た。RP−Ab
法における陜性・陰性は沈降線の有無により刀定
した。この時、粟補したRPを陜性察照、RPを含
たないこずを確認ずみの血挿を陰性察照ずしお各
テスト毎においた。RAテストは補造元胜曞にし
たが぀お刀定した。結果を第衚に瀺す。
The present invention relates to an antibody (hereinafter referred to as RP-Ab) specific to a rheumatoid arthritis-specific protein (hereinafter referred to as RP) isolated from rheumatoid plasma such as rheumatoid arthritis. Diagnosis of rheumatism currently relies largely on the doctor's findings and the patient's chief complaint, and the reality is that objective, quantitative diagnostic methods are desired. This diagnostic method generally uses the American Rheumatology Association's diagnostic criteria consisting of 11 items, and rheumatism is diagnosed based on how many of these items are met. One of the standard items is the detection of rheumatoid factor, and because the measurement method is simple, rheumatoid factor detection is widely performed as a routine test. By the way, rheumatoid factor is found at a high rate in the plasma of rheumatoid patients (depending on the report, rheumatoid factor has been detected in 40-70% of rheumatoid patients), but rheumatoid factor is detected in patients with non-rheumatoid conditions such as liver disease patients and cancer patients. It is frequently found in the plasma of patients with cirrhosis (more than 50% of patients with liver cirrhosis and nearly 20% of cancer patients are reported to be rheumatoid factor positive), and it is also found in 3-7% of healthy people. There is. Thus, the specificity of the presence of rheumatoid factors in rheumatism is low;
A diagnosis of rheumatism cannot be made immediately based on the presence of rheumatoid factor. Even in the diagnostic criteria of the American Rheumatism Association, the presence of rheumatoid factor is not recognized as a necessary or sufficient condition for the diagnosis of rheumatism. In other words, measuring rheumatoid factors has little practical utility in definitively diagnosing rheumatism, and therefore there is a need for parameters for rheumatoid diagnosis that can replace rheumatoid factors. As a result of research on the plasma of many rheumatism patients, patients with other diseases, and healthy people, the present inventors found that
Two-dimensional electrophoresis (hereinafter referred to as RP), which does not use a protein denaturing agent, was used to confirm that a novel protein (RP), which is not observed in the plasma of patients with other diseases or healthy individuals, is expressed at a high rate in the plasma of rheumatoid arthritis patients. 2-dimensional electrophoresis (all without using protein denaturants),
We were able to successfully isolate this RP and obtain an antibody RP-Ab specific to this RP. According to our research results, RP is 70 to 80% in rheumatoid arthritis patients.
Furthermore, it was not observed at all in healthy subjects, patients with renal failure, patients with liver disease, or patients with cancer. The previously known rheumatoid factor is positive in 40-70% of rheumatoid patients, and is also found at a high rate in healthy people, liver disease patients, and cancer patients. The positive rates for both cases are clearly high. Therefore, RP
By creating an antibody specific to RP-Ab and using a diagnostic agent using RP-Ab, RP can be used as a routine clinical test.
Detection can be an effective means of diagnosing rheumatism. Obtained for the creation of this RP-Ab
RP is necessary and therefore useful in rheumatism diagnosis.
Both RP and RP-Ab are extremely useful. When RP performs two-dimensional electrophoresis of rheumatoid plasma,
It is a protein with a molecular weight of approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis, with an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) as spots in the range of 0.40 to 0.55. . In two-dimensional electrophoresis of healthy human plasma, no proteins were observed in the range of isoelectric point (pI) of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. It turns out that RP is a completely new, previously unknown protein found in rheumatoid plasma. Next, we will discuss how to obtain RP. RP is
Rheumatoid plasma obtained by a general method can be separated on a two-dimensional electrophoresis gel by a two-dimensional electrophoresis method in which rheumatoid plasma is first subjected to isoelectric focusing using a polyacrylamide gel, followed by concentration gradient gel electrophoresis. . RP has an isoelectric point (pI) of 7.3 to 7.8 on a two-dimensional electrophoresis gel and a mobility of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). It can be isolated by dividing and extracting with a buffer or the like. RP isolated at this time
The molecular weight of is approximately 170,000 as determined by SDS polyacrylamide gel electrophoresis. In addition, in order to isolate a large amount of RP, the precipitate salted out with 25-35% saturated ammonium sulfate from rheumatoid patient plasma should be prepared using DEAE
Perform ion exchange chromatography using an ion exchange gel such as 50 (manufactured by Faymacia, Sweden), and collect the fraction eluted with 0.5 M sodium chloride. Furthermore, this fraction was added to Cefacryl S-300 (manufactured by Pharmacia, Sweden).
It can be isolated by performing gel chromatography using a gel such as the above gel, and then performing ion exchange chromatography using the above-mentioned ion exchange gel again. When subjected to two-dimensional electrophoresis, the RP isolated at this time had an isoelectric point (pI) of 7.3 to 7.8 and a mobility (assuming the mobility of the leading edge of albumin to 1.0) in the range of 0.40 to 0.55. It exhibits a molecular weight of approximately 170,000 when determined by gel electrophoresis. RP-specific antibody RP-Ab can be purified, e.g.
It can be obtained by a general method for producing specific antibodies, which involves immunizing an immunizable animal with RP together with Freund's complete adjuvant, etc., and collecting and purifying antiserum from the immunized animal. For purification of antibodies from antiserum, for example, the antigen RP is bound to a gel such as Sepharose 4B (manufactured by Pharmacia, Sweden) using a ligand such as cyanogen bromide, and
The antiserum is passed through a column filled with the gel, and after thorough washing, the antibody is separated from the column using a glycine buffer or the like using an immunoadsorption method or the like. The antibody RP-Ab obtained in this way can be confirmed to specifically react with purified RP to produce a precipitation line using general specific antibody confirmation methods such as immunoelectrophoresis or immunoprecipitation reaction. Can be confirmed. Measurement of RP in plasma using RP-Ab can be performed using currently commonly used antigen measurement methods using specific antibodies, such as double immunodiffusion using a gel such as agar, or RP in latex or red blood cells. It can be performed by various agglutination reactions performed by immobilizing -Ab, or by immunoassay using enzymes, radioisotopes, etc. by adsorbing RP-Ab onto a solid phase such as beads or microplates. RP can be easily measured using RP-Ab by such a measurement method, and therefore RP-Ab is important as a routine test method for rheumatism diagnosis. (Example) <Method for isolating RP> The precipitate precipitated with 25% saturated ammonium sulfate from excreted plasma generated by plasma exchange in rheumatoid arthritis patients with RP was collected at 8000 x g.
The supernatant was removed by centrifugation for 20 minutes, ammonium sulfate was further added to the supernatant, and the precipitate precipitated with 35% saturated ammonium sulfate was collected by centrifugation at 8000 xg for 20 minutes. This precipitate was dissolved in 0.02M phosphate buffer (PH7.2, hereinafter referred to as PBNa) and dialyzed against deionized water through a cellophane membrane to remove ammonium sulfate. Ion exchange chromatography was performed using an A-50 (manufactured by Pharmacia, Sweden) column. It was confirmed by two-dimensional electrophoresis that RP was contained in the fraction eluted with 0.5M sodium chloride solution, and this fraction was collected. The collected fractions were dialyzed twice against deionized water through a cellophane membrane to remove sodium chloride, concentrated by freeze-drying, and then subjected to gel chromatography using a Sephacryl S-300 (Pharmacia, Sweden) column. By collecting the fractions corresponding to the fraction positions where RP was confirmed by two-dimensional electrophoresis, it was possible to detect contamination by ion-exchange chromatography.
We separated substances with different behavior between RP and molecular sieve.
After this, further separation was performed based on ionic strength by ion exchange chromatography using a DEAE-Sephadex A-50 (manufactured by Pharmacia, Sweden) column, and sodium chloride was separated.
Purified RP was obtained by elution with a concentration gradient solution from 0.0M to 0.6M, and fractions corresponding to fractional positions where RP was confirmed by two-dimensional electrophoresis were collected. Using this purified RP as a sample, perform the following two steps.
It was confirmed by dimensional electrophoresis. refined
Add 60ÎŒl of RP (protein concentration 0.40mg/ml) to Ampholine (manufactured by Pharmacia, 6.25w/v).
% (PH3.5-10:PH3.5-5=4:1)] on a polyacrylamide gel containing 0.01M phosphoric acid solution.
Using a 0.04M sodium hydroxide solution, electrophoresis was performed at a constant current (2 mA) at first, and after the voltage reached 220 V, electrophoresis was performed at a constant voltage of 220 V for 20 hours. . next,
This running gel was placed on a polyacrylamide slab gel with a concentration gradient of 4% to 17% and run at constant current (24 mA) for 20 hours. A 0.05M Tris-0.384M glycine buffer was used as the electrophoresis solution at this time. After two-dimensional electrophoresis as described above, 0.025% Coomersie Brilliant Blue (Coomersie Brilliant Blue R-250), 50v/v
% methanol, 7% acetic acid solution for 8 hours, 7%
FIG. 1 shows an electrophoretic image obtained by decolorizing with acetic acid and 10% methanol solution for 3 days. The electrophoresis image has an isoelectric point of 7.3 to 7.8,
It was confirmed that it was RP because the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). Also, the RP obtained at this time is SDS
The molecular weight was determined to be approximately 170,000 by polyacrylamide gel electrophoresis. For reference, two-dimensional electrophoresis images of plasma from patients with rheumatoid arthritis and plasma from healthy individuals are shown in FIGS. 2 and 3, respectively. In a two-dimensional electrophoresis image of plasma from a patient with rheumatoid arthritis, spots of RP are seen within the range of isoelectric point 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin is 1.0) of 0.40 to 0.55 (dashed line). ). However, in a two-dimensional electrophoretic image of plasma from a healthy person, there are not only RP but also protein spots within the isoelectric point of 7.3 to 7.8 and mobility (assuming the mobility of the leading edge of albumin to 1.0) of 0.40 to 0.55. is not accepted at all. Purified RP has maximum absorption at 280 nm in the UV spectrum, is ninhydrin positive, and
RA test, RAHA, and Immune Complex test are performed to determine if RP is a known rheumatoid factor or
It was also confirmed at times that it was not an Immune Complex. Furthermore, after hydrolyzing the purified RP with 6N hydrochloric acid at 110℃ for 24 hours,
Amino acid analysis was performed by . The results obtained at this time were as follows (unit: mole%). Lys6.6, His1.9, Arg4.0, Asp7.0, Thr8.5,
Ser10.0, Glu10.4, Pro7.9, Gly10.4, Ala4.7,
Cys/2 1.0, Val7.5, Met1.6, Ile2.9,
Leu8.3, Tyr4.5, Phe2.9 <Creation of RP-Ab> 1ml of purified RP using a domestic rabbit as the immunized animal
(protein content: 0.32 mg) was mixed with 1 ml of Freund's complete adjuvant to prepare a stable water-in-oil emulsion, which was injected subcutaneously into adult rabbits. After one month, 1 ml of purified RP (protein content 0.40)
mg) and 1 ml of Freund's complete adjuvant, a stable water-in-oil emulsion was again prepared and injected subcutaneously into the same rabbit. After another week, blood was collected to obtain antiserum. Antibody was purified from antiserum as follows. First, 20 ml of Cephalose 4B (manufactured by Pharmacia, Sweden) was pre-washed with distilled water on a Buchner funnel, and 20 ml of distilled water and aqueous cyanogen bromide solution (2 g/40 ml) were added to it, and 4N sodium hydroxide was added. The pH was immediately set to 11.0. This was stirred for 8 minutes while maintaining the pH between 11.0 and 11.3, and after 8 minutes, the gel was suction filtered using a BÃŒtzfner funnel, and the gel on the funnel was cooled with 0.1 mol sodium carbonate buffer (PH 9.0). It was washed three times with water, filtered with suction, drained and placed in an ice water bath. Separately,
20ml of purified RP was dialyzed against sodium carbonate buffer using a cellophane membrane, and the ice-cooled product was added to the prepared gel in an ice water bath and stirred for 10 minutes to prepare an antigen-binding gel. . . After packing this antigen-binding gel into a column and washing it with PBNa,
Pour 10 ml of antiserum obtained from a domestic rabbit to remove RP in the antiserum.
-Ab was adsorbed to antigen-binding gel. After thorough washing with PBNa, RP-Ab was collected by running a pH 2.3 glycine buffer (0.17M) through the column, and immediately adding 1/10 volume of a PH 11.5 glycine buffer (1M). After neutralization, RP-Ab was purified and isolated. refined
RP-Ab was confirmed as follows. First, purified RP was developed by two-dimensional electrophoresis, and then a mixture of 0.5 ml of purified RP-Ab in 1% agar was poured onto the gel that had been developed by two-dimensional electrophoresis. After the agar solidified, it was left at room temperature for one day to perform the immunoprecipitation reaction. The precipitated spots formed on the agar after the immunoprecipitation reaction are
The isoelectric point was within the range of 7.3 to 7.8, and the mobility was within the range of 0.40 to 0.55 (assuming the mobility of the leading edge of albumin to be 1.0). The sedimentation spots obtained at this time are shown in Figure 4.
It was shown that RP-Ab, an antibody specific to RP, could be purified. <Examples of rheumatism diagnosis using RP-Ab> 60 patients with rheumatoid arthritis, 30 healthy individuals, 20 patients with renal failure, 12 patients with liver disease (cirrhosis, etc.), cancer patients ( For 40 cases (gastric cancer, colorectal cancer, etc.), double immunodiffusion method using RP-Ab and rheumatoid factor measurement using a commercially available RA test kit (manufactured by Nissui Pharmaceutical Co., Ltd.) (hereinafter referred to as RP-Ab method and RA Diagnosis of rheumatism was made using the test. RP-Ab
Positive or negative test results were determined by the presence or absence of sedimentation lines. At this time, purified RP was used as a positive control, and plasma, which had been confirmed not to contain RP, was used as a negative control for each test. The RA test was determined according to the manufacturer's instructions. The results are shown in Table 1.

【衚】 慢性関節リりマチ患者におけるRP−Ab法によ
る陜性率が76.7停陰性23.3であ぀たのに
察しお、RAテストによる陜性率は60.0停陰
性40.0であり、感床はRAテストに比べおRP
−Ab法の方が明らかに高か぀た。たた、健垞人、
腎䞍党患者、肝疟患患者および癌患者においお
は、RP−Ab法では党く停陜性が認められなか぀
たのに察しお、RAテストでは疟患によ぀お異な
るものの6.0〜33.3もの停陜性が認められ、RA
テストに比べおRP−Ab法の方が明らかに特異性
は高か぀た。以䞊の結果より、埓来甚いられおい
るリりマチ因子の枬定による方法に比べお、RP
−Ab法によるリりマチ蚺断法は明らかに優れお
おり、RP−Abがリりマチ蚺断における日垞怜査
に非垞に有甚であるこずが瀺された。
[Table] The positive rate of the RP-Ab method in patients with rheumatoid arthritis was 76.7% (23.3% false negative), while the positive rate of the RA test was 60.0% (40.0% false negative), indicating that sensitivity is RP compared to RA test
-Ab method was clearly higher. Also, healthy people,
In patients with renal failure, liver disease, and cancer, the RP-Ab method had no false positives, whereas the RA test had false positives of 6.0% to 33.3%, depending on the disease. , R.A.
The RP-Ab method was clearly more specific than the test. From the above results, compared to the conventional method of measuring rheumatoid factor, RP
The rheumatism diagnosis method using the -Ab method is clearly superior, and it has been shown that RP-Ab is very useful for routine tests in rheumatism diagnosis.

【図面の簡単な説明】[Brief explanation of the drawing]

第図は粟補RPの次元電気泳動像、第図
は慢性関節リりマチ患者血挿の次元電気泳動
像、第図は健垞人血挿の次元電気泳動像、第
図はRP−Abの沈降スポツトである。
Figure 1 is a two-dimensional electrophoretic image of purified RP, Figure 2 is a two-dimensional electrophoretic image of rheumatoid arthritis patient plasma, Figure 3 is a two-dimensional electrophoretic image of healthy human plasma, and Figure 4 is RP-Ab. It is a sedimentation spot.

Claims (1)

【特蚱請求の範囲】  SDSポリアクリルアミドゲル電気泳動で玄
170000の分子量を瀺し、蛋癜倉性剀を甚いない
次元電気泳動における等電点が7.3〜7.8、移動床
アルブミン最先端郚の移動床を1.0ずしおが
0.40〜0.55の範囲にあり、アミノ酞組成が䞋蚘の
ずおりである、リりマチ血挿䞭より取埗されたリ
りマチ特異蛋癜質により䜜成されたリりマチ特異
蛋癜質に察する抗䜓。 アミノ酞組成 Lys6.6、His1.9、Arg4.0、Asp7.0、Thr8.5、
Ser10.0、Glu10.4、Pro7.9、Gly10.4、Ala4.7、
Cys 1.0、Val7.5、Met1.6、Ile2.9、Leu8.3、
Tyr4.5、Phe2.9
[Claims] 1. Approx.
Shows a molecular weight of 170,000 and does not use protein denaturants2
The isoelectric point in dimensional electrophoresis is 7.3-7.8, and the mobility (assuming the mobility of the leading edge of albumin is 1.0)
An antibody against a rheumatoid-specific protein produced from a rheumatoid-specific protein obtained from rheumatoid plasma, which is in the range of 0.40 to 0.55 and has the following amino acid composition. (Amino acid composition) Lys6.6, His1.9, Arg4.0, Asp7.0, Thr8.5,
Ser10.0, Glu10.4, Pro7.9, Gly10.4, Ala4.7,
Cys/2 1.0, Val7.5, Met1.6, Ile2.9, Leu8.3,
Tyr4.5, Phe2.9
JP24249090A 1990-09-14 1990-09-14 Antibody to rheumatism-specific protein Granted JPH03218464A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP24249090A JPH03218464A (en) 1990-09-14 1990-09-14 Antibody to rheumatism-specific protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24249090A JPH03218464A (en) 1990-09-14 1990-09-14 Antibody to rheumatism-specific protein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP58053922A Division JPS59180363A (en) 1983-03-31 1983-03-31 Rheumatic specific protein and antibody thereof

Publications (2)

Publication Number Publication Date
JPH03218464A JPH03218464A (en) 1991-09-26
JPH0541640B2 true JPH0541640B2 (en) 1993-06-24

Family

ID=17089863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24249090A Granted JPH03218464A (en) 1990-09-14 1990-09-14 Antibody to rheumatism-specific protein

Country Status (1)

Country Link
JP (1) JPH03218464A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5475358B2 (en) * 2009-08-04 2014-04-16 ホヌナヌ株匏䌚瀟 Two-dimensional electrophoresis method

Also Published As

Publication number Publication date
JPH03218464A (en) 1991-09-26

Similar Documents

Publication Publication Date Title
Kawai Clinical aspects of the plasma proteins
Tomasi et al. The selective occurrence of γ 1 A globulins in certain body fluids
Osserman et al. Clinical and immunochemical studies of four cases of heavy (Hγ2) chain disease
CA1183451A (en) Method for producing a csap tryptic peptide and anti- csap antibodies
Linder et al. Assay of tissue ferritin
Olsen Methadone binding to human plasma proteins
JPS59225196A (en) Tissue protein and isolation
EP0332651B2 (en) Method of isolating ca 125 antigen
Kohanteb et al. Detection of Leishmania donovani soluble antigen and antibody in the urine of visceral leishmaniasis patients
FI61192B (en) PROCEDURE FOR THE FRAMEWORK OF ETA SAOSOM DIAGNOSTIC MEDEL ANVAENDBART VAEVNADSPROTEIN
Holmberg et al. Immunologic studies in haemophilia A
GB2143239A (en) Human granulocyte l1 proteins
Echetebu et al. Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase.
JPS62501563A (en) Proteins characteristic of rheumatoid arthritis
JP3562834B2 (en) Test method for DAF molecules in stool
JPH0354679B2 (en)
Tschopp et al. Occurrence of an incomplete C8 molecule in homozygous C8 deficiency in man.
Wells et al. Antibodies to human collagen in subjects with selective IgA deficiency
Green et al. Urinary loss of clotting factors due to hereditary membranous glomerulopathy
Patterson et al. An IgM pyroglobulin associated with lymphosarcoma
Wallwork et al. The SIgA system and hypersensitivity in patients with cystic fibrosis
JPH0541640B2 (en)
JPH0526800B2 (en)
US4559311A (en) Diagnostic method using oncofetal peptide as a tumor marker
Glueck et al. A monoclonal immunoglobulin A (κ) factor VIII: C inhibitor associated with primary amyloidosis: Identification and characterization